10:58 AM EDT, 04/25/2024 (MT Newswires) -- AbbVie ( ABBV ) said Thursday that data from a phase 3b/4 trial enrolling adults and adolescents with atopic dermatitis showed that Rinvoq had "superior efficacy" against Dupixent in the primary endpoint.

The primary goal of the study was the simultaneous achievement of near-complete skin clearance and no to little itch, the company said.

Rinvoq also demonstrated superiority over Dupixent for "all ranked secondary endpoints, including the rapid onset of achieving near-complete skin clearance and no to little itch," AbbVie ( ABBV ) said.

Rinvoq, which is being developed by AbbVie ( ABBV ), is being studied in several immune-mediated inflammatory diseases, the company said.

Abbvie ( ABBV ) shares were down 1% in recent trading.

Price: 166.09, Change: -1.71, Percent Change: -1.02